Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for oncology and other high unmet clinical needs, has reported its financial results for the second quarter ending June 30, 2026. The company also provided an update on various corporate developments.
Dr. Steven Quay, President and CEO of Atossa, noted that the company made significant progress during the quarter by advancing the scientific rationale for (Z)-endoxifen’s potential applications in rare pediatric diseases, such as Duchenne Muscular Dystrophy and McCune-Albright Syndrome. Atossa presented new data at key industry conferences including ASCO and AACR, along with publications in the peer-reviewed journals Degenerative Neurological and Neuromuscular Disease and npj Breast Cancer.
Recently, Atossa participated in the AACR Special Conference where it discussed the dual mechanism of action for (Z)-endoxifen in treating estrogen-driven pathology related to McCune-Albright Syndrome. The company has received Rare Pediatric Disease designation from the FDA for (Z)-endoxifen for this indication, as well as for Duchenne Muscular Dystrophy.
In terms of clinical activities, Atossa announced an ongoing clinical trial, EVANGELINE, which evaluates (Z)-endoxifen's efficacy as a neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer. Enrollment for this study was completed by June 30, 2026. Additionally, the company detailed a recent publication that highlights the anti-cancer activity of (Z)-endoxifen-related compounds across various breast cancer models.
Financially, Atossa reported total operating expenses of $8.7 million for the three months ended June 30, 2026, a decrease from $9.0 million during the same period in 2025. The company raised $4.5 million through a registered direct offering, with an additional potential $12 million through warrant exercises. The proceeds will support ongoing clinical development and general corporate working capital.